Transarterial chemoembolization (TACE), a minimally invasive procedure for liver cancer, is an effective treatment strategy for patients with large, asymptomatic, or multifocal hepatocellular ...

Lenvatinib (Lenv) plus tislelizumab (Tis) combined with or without transarterial chemoembolization (TACE) in first-line treatment of unresectable hepatocellular carcinoma (uHCC): A prospective, ...

Combining TACE and SBRT offers a promising treatment for large HCC tumors, addressing TACE's limitations in intermediate-stage cases. Technological advancements have improved SBRT's precision and ...

In this review we will discuss TACE, TAE and TOCE in detail. The TACE procedure consists of the injection of anticancer drugs mixed with or without lipiodol into the hepatic artery followed by the ...

SAN FRANCISCO -- After more than 20 years of trying, systemic therapy for unresectable liver cancer has improved outcomes with transarterial chemoembolization (TACE), a randomized trial showed.

There's a possible new standard of care on the horizon for unresectable hepatocellular carcinoma (HCC) after years of failed attempts to improve upon the outcomes of the current protocol — stand-alone ...

Please provide your email address to receive an email when new articles are posted on . Postprocedural imaging showed 10% of patients had new portal vein thrombosis after transarterial ...

Tick marks indicate censoring of data. No participants had an albumin-bilirubin grade of 3, so this group has not been included in subgroup definitions here. BCLC=Barcelona Clinic Liver Cancer.

Hepatocellular carcinoma (HCC) is the most commonly diagnosed cancer of the liver and the fourth leading cause of cancer-related mortality worldwide, with China accounting for over half of the global ...

Please provide your email address to receive an email when new articles are posted on . Transarterial chemoembolization plus vitamin K prolonged progression-free survival compared with TACE alone (262 ...

The study’s senior author discusses how the combined mechanisms of action produced benefit in progression-free survival. Results presented today at the American Society of Clinical Oncology ...